Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Retained Earnings (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Retained Earnings for 8 consecutive years, with -$118000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings rose 99.98% year-over-year to -$118000.0, compared with a TTM value of -$118000.0 through Sep 2025, up 99.98%, and an annual FY2024 reading of -$515.4 million, down 7.84% over the prior year.
  • Retained Earnings was -$118000.0 for Q3 2025 at X4 Pharmaceuticals, up from -$138000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at -$118000.0 in Q3 2025 and bottomed at -$515.4 million in Q4 2024.
  • Average Retained Earnings over 5 years is -$272.1 million, with a median of -$304.8 million recorded in 2022.
  • The sharpest move saw Retained Earnings crashed 385446.22% in 2023, then soared 99.98% in 2025.
  • Year by year, Retained Earnings stood at -$282.9 million in 2021, then plummeted by 33.18% to -$376.7 million in 2022, then dropped by 26.85% to -$477.9 million in 2023, then fell by 7.84% to -$515.4 million in 2024, then surged by 99.98% to -$118000.0 in 2025.
  • Business Quant data shows Retained Earnings for XFOR at -$118000.0 in Q3 2025, -$138000.0 in Q2 2025, and -$515.1 million in Q1 2025.